FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199759922> ?p ?o ?g. }

• W3199759922 endingPage "2835" @default.
• W3199759922 startingPage "2826" @default.
• W3199759922 abstract "Candida albicans is a life-threatening, opportunistic fungal pathogen with a high mortality rate, especially within the immunocompromised populations. Multidrug resistance combined with limited antifungal drugs even worsens the situation. Given the facts that the current drug discovery strategies fail to deliver sufficient antifungals for the emerging multidrug resistance, we urgently need to develop novel approaches. By systematically investigating what caused the different antifungal activity of rapamycin in RPMI 1640 and YPD, we discovered that peptide-like compounds can generate a hyper-synergistic antifungal effect with rapamycin on both azole-resistant and sensitive clinical C. albicans isolates. The minimum inhibitory concentration (MIC) of rapamycin reaches as low as 2.14 nM (2-9 μg/mL), distinguishing this drug combination as a hyper-synergism by having a fractional inhibitory concentration (FIC) index ≤ 0.05 from the traditional defined synergism with an FIC index < 0.5. Further studies reveal that this hyper-synergism orthogonally targets the protein Tor1 and affects the TOR signaling pathway in C. albicans, very likely without crosstalk to the stress response, Ras/cAMP/PKA, or calcineurin signaling pathways. These results lead to a novel strategy of controlling drug resistant C. albicans infection in the immunocompromised populations. Instead of prophylactically administering other antifungals with undesirable side-effects for extended durations, we now only need to coadminister some nontoxic peptide additives. The novel antifungal strategy approached in this study not only provides a new therapeutic method to control fungal infections in rapamycin-taking immunocompromised patients but also mitigates the immunosuppressive side-effects of rapamycin, repurposing rapamycin as an antifungal agent with wide applications." @default.
• W3199759922 created "2021-09-27" @default.
• W3199759922 creator A5004388687 @default.
• W3199759922 creator A5008746029 @default.
• W3199759922 creator A5012841530 @default.
• W3199759922 creator A5014844829 @default.
• W3199759922 creator A5023579325 @default.
• W3199759922 creator A5025851882 @default.
• W3199759922 creator A5047744034 @default.
• W3199759922 creator A5048518576 @default.
• W3199759922 creator A5050728251 @default.
• W3199759922 creator A5069597628 @default.
• W3199759922 creator A5070025475 @default.
• W3199759922 creator A5076921758 @default.
• W3199759922 creator A5077871312 @default.
• W3199759922 creator A5080798079 @default.
• W3199759922 creator A5088254472 @default.
• W3199759922 date "2021-09-13" @default.
• W3199759922 modified "2023-10-16" @default.
• W3199759922 title "Hyper-Synergistic Antifungal Activity of Rapamycin and Peptide-Like Compounds against <i>Candida albicans</i> Orthogonally via Tor1 Kinase" @default.
• W3199759922 cites W1494395715 @default.
• W3199759922 cites W1811665544 @default.
• W3199759922 cites W1965575582 @default.
• W3199759922 cites W1972736746 @default.
• W3199759922 cites W1979749196 @default.
• W3199759922 cites W1991488616 @default.
• W3199759922 cites W1991691392 @default.
• W3199759922 cites W2001881651 @default.
• W3199759922 cites W2003564377 @default.
• W3199759922 cites W2008873399 @default.
• W3199759922 cites W2016007336 @default.
• W3199759922 cites W2016562927 @default.
• W3199759922 cites W2016618027 @default.
• W3199759922 cites W2020653359 @default.
• W3199759922 cites W2024431372 @default.
• W3199759922 cites W2033070135 @default.
• W3199759922 cites W2033288552 @default.
• W3199759922 cites W2057106513 @default.
• W3199759922 cites W2063013559 @default.
• W3199759922 cites W2064587638 @default.
• W3199759922 cites W2087136249 @default.
• W3199759922 cites W2088947878 @default.
• W3199759922 cites W2093920981 @default.
• W3199759922 cites W2098563304 @default.
• W3199759922 cites W2103562758 @default.
• W3199759922 cites W2108989058 @default.
• W3199759922 cites W2109785145 @default.
• W3199759922 cites W2119749825 @default.
• W3199759922 cites W2120356140 @default.
• W3199759922 cites W2121212490 @default.
• W3199759922 cites W2127142654 @default.
• W3199759922 cites W2140712528 @default.
• W3199759922 cites W2141563676 @default.
• W3199759922 cites W2144149632 @default.
• W3199759922 cites W2150023843 @default.
• W3199759922 cites W2151254944 @default.
• W3199759922 cites W2157531964 @default.
• W3199759922 cites W2159171427 @default.
• W3199759922 cites W2332534830 @default.
• W3199759922 cites W2517054293 @default.
• W3199759922 cites W2537975785 @default.
• W3199759922 cites W2604219750 @default.
• W3199759922 cites W2626632314 @default.
• W3199759922 cites W2770313364 @default.
• W3199759922 cites W2770849724 @default.
• W3199759922 cites W3116201711 @default.
• W3199759922 cites W4251278858 @default.
• W3199759922 doi "https://doi.org/10.1021/acsinfecdis.1c00448" @default.
• W3199759922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34514778" @default.
• W3199759922 hasPublicationYear "2021" @default.
• W3199759922 type Work @default.
• W3199759922 sameAs 3199759922 @default.
• W3199759922 citedByCount "12" @default.
• W3199759922 countsByYear W31997599222022 @default.
• W3199759922 countsByYear W31997599222023 @default.
• W3199759922 crossrefType "journal-article" @default.
• W3199759922 hasAuthorship W3199759922A5004388687 @default.
• W3199759922 hasAuthorship W3199759922A5008746029 @default.
• W3199759922 hasAuthorship W3199759922A5012841530 @default.
• W3199759922 hasAuthorship W3199759922A5014844829 @default.
• W3199759922 hasAuthorship W3199759922A5023579325 @default.
• W3199759922 hasAuthorship W3199759922A5025851882 @default.
• W3199759922 hasAuthorship W3199759922A5047744034 @default.
• W3199759922 hasAuthorship W3199759922A5048518576 @default.
• W3199759922 hasAuthorship W3199759922A5050728251 @default.
• W3199759922 hasAuthorship W3199759922A5069597628 @default.
• W3199759922 hasAuthorship W3199759922A5070025475 @default.
• W3199759922 hasAuthorship W3199759922A5076921758 @default.
• W3199759922 hasAuthorship W3199759922A5077871312 @default.
• W3199759922 hasAuthorship W3199759922A5080798079 @default.
• W3199759922 hasAuthorship W3199759922A5088254472 @default.
• W3199759922 hasConcept C103637391 @default.
• W3199759922 hasConcept C114851261 @default.
• W3199759922 hasConcept C133936738 @default.
• W3199759922 hasConcept C145081991 @default.
• W3199759922 hasConcept C176947019 @default.
• W3199759922 hasConcept C200082930 @default.
• W3199759922 hasConcept C2779281246 @default.

• next